Merrell Dow Pharmaceuticals

National Research Development Corporation

Merrell Toraude Et Compagnie

Merrell Pharmaceuticals, Inc.

Other

Prestwick Pharmaceuticals, Inc.

Maurice W Gittos

Marcel Hibert

John R Fozard

Gerard J Letertre

Francis P Miller

Michael G Palfreyman

Hsien C Cheng

Michael Spedding

Stephen M Sorensen

Paul Moser

Marcel Hilbert

David A Amey

Novel bisulphate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnea. The preferred bisulphate salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate.

Piperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders

This invention relates to novel amide derivatives of certain 2,6-methano-2H-quinolizine-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT.sub.3 receptors, and to their end-use application in the treatment of chemotherapeutically-induced nausea and vomiting, as anti-anxiety agents, in the symptomatic treatment of pain associated with migraine, as anti-arrhythmic agents, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia, and mania, in the treatment of glaucoma, for stimulating gastric motility, to combat drug abuse, to treat sleep apnea and to treat irritable bowel syndrome.

Derivatives of amide analogs of certain methano bridged quinolizines

This invention relates to the manufacture of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines and their use as medicaments in the treatment of cognitive disorders.

Use of certain esters of

2,6-methano-2H-quinolizin derivative as 5-HT.sub.3 -receptor antagonist

The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma and for the stimulation of gastric motility.

Medicament compositions derived from quinolizine and quinolizinone and

Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents methoxy, ethoxy or hydroxy,

Method for potentiating an immune response with derivatives

This invention relates to aromatic 2-aminoalkyl derivatives of 1,2-benzoisothiazol-3(2H)one-1,1-dioxides, processes for the preparation of same, and to their use as anxiolytic and antihypertensive agents.

Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide

Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3-(2H)one-1,1-dioxide and

Pharmaceutical compositions and medical uses of dioxopiperidine

The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.

Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and

Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)-one-1,1-dioxide

Growing community of inventors

Plobsheim, France

Maurice W Gittos